About the Company
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
90
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SURF News
The Resilience of Monoclonal Antibodies and their Makers
The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes ...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter ...
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
On March 7, 2024, ALX Oncology Holdings Inc (NASDAQ:ALXO) released its 8-K filing ... a CD47 blocker in phase 1 and 2 clinical trials. CD47 is a cell surface protein that cancer cells exploit to evade ...
Key Health Care Issues to Track in 2024 in Alabama
[i] In North Alabama, Huntsville Emergency Medical Services Inc. (HEMSI) merged with the Huntsville Hospital Health System as of January 2024. [ii] 3. Expansion of Healthcare Providers. In an effort ...
Studying use of patients’ own reprogrammed cells to attack cancer as alternative to more chemo
A process of taking patients’ own cells and reprogramming them to fight cancer has been a last-ditch option for blood cancer ...
Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors
“That was shocking to me,” said Dr. Otis Brawley, a professor of oncology at Johns Hopkins University and ... in a lab so they’d recognize and bind to specific proteins on the surface of the brain ...
Merck & Co., Inc.: Merck Looks Well Positioned With Keytruda, Gardasil, and a Strengthening Pipeline
Find the latest Merck & Company, Inc. (MRK) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative ...
1 (Bad) Reason to Sell Moderna Stock Right Now, and 2 Good Reasons to Buy It
It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA) ...
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
NDAQ:KYTX) Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis ...
FDA Clears Clinical Study of Vaccine Therapy for Ovarian Cancer
The first-in-human study that has received FDA clearance will investigate the novel autologous Innocell vaccine in stage ...
Q4 2023 Heron Therapeutics Inc Earnings Call
Kevin Warner; SVP of Medical Affairs strategy engagements; Heron Therapeutics Inc William Forbes; EVP, Chief Development Officer; Heron Therapeutics Inc Ira Duarte; Chief Financial Officer; Heron ...
Loading the latest forecasts...